TauRx launches late-stage Alzheimer's studies; BioCryst scraps hep C study after FDA pushes back on safety; Seattle Genetics wins $25M milestone;

 @FierceBiotech: Ipsen braces for $153M write-off as troubled biotech partner declares bankruptcy. News | Follow @FierceBiotech

 @JohnCFierce: Biocon (India) scouts R&D pact after GE unit grabs stake in research division. Story | Follow @JohnCFierce

 @RyanMFierce: Biotech's boneyard: 2012 report on the dead, dying, disabled (and some reborn) biotech operations. Happy Halloween! Special Report | Follow @RyanMFierce

> Singapore-based TauRx has grabbed headlines with its launch of a pair of late-stage studies for a new Alzheimer's therapy. Diverging from the common beta amyloid approach, TauRx is looking to block tau, a protein that triggers tangles inside of brain cells found in Alzheimer's patients. Story

> BioCryst's ($BCRX) plans to build an ambitious hep C effort have run into some serious trouble. The biotech says it scrapped plans for an early-stage study of BCX5191 after the FDA concluded that it presented a toxicity threat to patients. It's a nucleoside program and the latest drug to fall victim to the agency's safety alarms after Bristol-Myers Squibb's ($BMY) nuc--BMS-094--was tanked after one patient died and others were injured in a study. Release

> Looking to expand its presence in the hot Chinese drug discovery and development industry, Charles River Laboratories purchased a majority interest in Vital River for $27 million. Report

> The European Commission has given Millennium a green light for Adcetris, which triggers a $25 million milestone for Seattle Genetics ($SGEN). Release

> EnVivo Pharmaceuticals has published additional positive data from its Phase IIb study of the Alzheimer's drug EVP-6124. Release

> TransTech Pharma says that it reaped positive data from a Phase IIb study of an experimental Alzheimer's drug. Report

Medical Device News

 @FierceMedDev: Boston Sci snagged EU approval for its new stent with bioabsorbable coating. News | Follow @FierceMedDev

 @MarkHFierce: Fidelity is investing $75M into Trivitron Healthcare, an Indian company focused on imaging and lab Dx. Release | Follow @MarkHFierce

 @DamianFierce: The latest Cleveland Clinic top 10 innovations list includes some novel medical devices. Article | Follow @DamianFierce

> GI Dynamics moves toward FDA approval for weight-loss tech. Story

> OptiScan, maker of glucose monitoring devices, raises $2.6M. Item

Pharma News

@FiercePharma: BMJ says no more clinical trial publications if actual data isn't open for outside review. More | Follow @FiercePharma

> Novo hikes forecast on 62% jump in Victoza sales. News

> BMJ editor flogs Roche for Tamiflu data secrecy. Story

> Novartis building new plant as pipeline fills with biologics. Article

Drug Delivery News

> Twice-yearly opioid dependence implant steps closer to the market. Item

> Ocular Therapeutix eyes up positive results for OTX-TP2. Article

> Starpharma technology delivers 40-fold more docetaxel to tumor. Report

> Paclitaxel particles extend life threefold in mouse bladder cancer. News

Biomarkers News

> Seeing is believing: Biomarkers visible to the naked eye. Item

> Blood biomarker tags NeuVax's role in breast cancer treatment. Article

> Marking glimpses of activity for Lilly's Alzheimer drug after PhIII struggles. Report

> U.K. researchers spot new marker for prostate cancer prognosis. News

> Chromosome cap length predicts pancreatic cancer risk. Story

And Finally… A new study says that a regular diet of fish can reduce the risk of stroke, but don't look for the same response by taking fish oil supplements. Release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.